Decorin Expression in Human Vulva Carcinoma: Oncosuppressive Effect of Decorin CDNA Transduction on Carcinoma Cells

Overview

Journal J Histochem Cytochem

Publisher Sage Publications

Specialty Biochemistry

Date 2019 Apr 23

PMID 31009269

Citations 2

Authors

Marie C Nyman

Anne B Jokilammi

Pia C Bostrom

Samu H Kurki

Annele O Sainio

Seija E Grenman

Katri J Orte

Sakari H Hietanen

Klaus Elenius

Hannu T Jarvelainen

Affiliations

Soon will be listed here.

Abstract

The extracellular matrix proteoglycan decorin is well-known for its oncosuppressive activity. Here, decorin expression was examined in human vulva carcinoma tissue samples and in primary and commercial cell lines representing this malignant disease. Furthermore, the effect of adenovirus-mediated decorin cDNA (Ad-DCN) transduction on the viability, proliferation, and the expression and activity of the epidermal growth factor receptor (ErbB/HER) family members of the cell lines were investigated. Using in situ hybridization and immunohistochemistry for decorin, it was demonstrated that malignant cells in human vulva carcinoma tissues lack decorin expression. This result was true independently on tumor stage, grade or human papillomavirus status. RT-qPCR analyses showed that the human vulva carcinoma cell lines used in this study were also negative for decorin expression. Transduction of the cell lines with Ad-DCN caused a marked reduction in cell viability, while the proliferation of the cells was not affected. Experiments examining potential mechanisms behind the oncosuppressive effect of Ad-DCN transduction revealed that ErbB2/HER2 expression and activity in carcinoma cells were markedly downregulated. In conclusion, the results of this study showed that human vulva carcinoma cells lack decorin expression, and that Ad-DCN transduction of these cells induces oncosuppressive activity in part via downregulation of ErbB2/HER2.

Citing Articles

Global impact of proteoglycan science on human diseases.

Xie C, Schaefer L, Iozzo R iScience. 2023; 26(11):108095.

PMID: 37867945 PMC: 10589900. DOI: 10.1016/j.isci.2023.108095.

Oncosuppressive roles of decorin through regulation of multiple receptors and diverse signaling pathways.

Xie C, Mondal D, Ulas M, Neill T, Iozzo R Am J Physiol Cell Physiol. 2022; 322(3):C554-C566.

PMID: 35171698 PMC: 8917911. DOI: 10.1152/ajpcell.00016.2022.

References

Iozzo R, Chakrani F, Perrotti D, McQuillan D, Skorski T, Calabretta B . Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci U S A. 1999; 96(6):3092-7. PMC: 15900. DOI: 10.1073/pnas.96.6.3092. View

Smid-Koopman E, Blok L, Chadha-Ajwani S, Helmerhorst T, Brinkmann A, Huikeshoven F . Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method. Br J Cancer. 2000; 83(2):246-51. PMC: 2363496. DOI: 10.1054/bjoc.2000.1238. View

Santra M, Eichstetter I, Iozzo R . An anti-oncogenic role for decorin. Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem. 2000; 275(45):35153-61. DOI: 10.1074/jbc.M006821200. View

Shridhar V, Lee J, Pandita A, ITURRIA S, Avula R, Staub J . Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 2001; 61(15):5895-904. View

Wu X, Xin Y, Yao J, Hasui K, Tsuyama S, Yonezawa S . Expression of epithelial growth factor receptor and its two ligands, transforming growth factor-alpha and epithelial growth factor, in normal and neoplastic squamous cells in the vulva: an immunohistochemical study. Med Electron Microsc. 2002; 34(3):179-84. DOI: 10.1007/s007950100013. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Reed C, Gauldie J, Iozzo R . Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene. 2002; 21(23):3688-95. DOI: 10.1038/sj.onc.1205470. View

Cohen R . Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2003; 2(4):246-51. DOI: 10.3816/CCC.2003.n.006. View

Tralhao J, Schaefer L, Micegova M, Evaristo C, Schonherr E, Kayal S . In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J. 2003; 17(3):464-6. PMC: 5913819. DOI: 10.1096/fj.02-0534fje. View

10.

Junttila T, Laato M, Vahlberg T, Soderstrom K, Visakorpi T, Isola J . Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res. 2003; 9(14):5346-57. View

11.

Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P . Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol. 2003; 15(1):28-32. DOI: 10.1093/annonc/mdh011. View

12.

Raitanen M, Worsham M, Lakkala T, Carey T, Van Dyke D, Grenman R . Characterization of 10 vulvar carcinoma cell lines by karyotyping, comparative genomic hybridization and flow cytometry. Gynecol Oncol. 2004; 93(1):155-63. DOI: 10.1016/j.ygyno.2003.12.033. View

13.

Reed C, Waterhouse A, Kirby S, Kay P, Owens R, McQuillan D . Decorin prevents metastatic spreading of breast cancer. Oncogene. 2005; 24(6):1104-10. DOI: 10.1038/sj.onc.1208329. View

14.

Seidler D, Goldoni S, Agnew C, Cardi C, Thakur M, Owens R . Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem. 2006; 281(36):26408-18. DOI: 10.1074/jbc.M602853200. View

15.

Brustmann H . Epidermal growth factor receptor is involved in the development of an invasive phenotype in vulvar squamous lesions, but is not related to MIB-1 immunoreactivity. Int J Gynecol Pathol. 2007; 26(4):481-9. DOI: 10.1097/pgp.0b013e3180555999. View

16.

Salomaki H, Sainio A, Soderstrom M, Pakkanen S, Laine J, Jarvelainen H . Differential expression of decorin by human malignant and benign vascular tumors. J Histochem Cytochem. 2008; 56(7):639-46. PMC: 2430166. DOI: 10.1369/jhc.2008.950287. View

17.

Growdon W, Boisvert S, Akhavanfard S, Oliva E, Dias-Santagata D, Kojiro S . Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol. 2008; 111(2):289-97. DOI: 10.1016/j.ygyno.2008.07.038. View

18.

Bjorkoy G, Lamark T, Pankiv S, Overvatn A, Brech A, Johansen T . Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol. 2009; 452:181-97. DOI: 10.1016/S0076-6879(08)03612-4. View

19.

Goldoni S, Humphries A, Nystrom A, Sattar S, Owens R, McQuillan D . Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol. 2009; 185(4):743-54. PMC: 2711571. DOI: 10.1083/jcb.200901129. View

20.

Baselga J, Swain S . Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009; 9(7):463-75. DOI: 10.1038/nrc2656. View